In most known temperate bacteriophages, prophage immunity is determined by a repressor protein which prevents transcription initiation at promoters controlling the expression of replication functions and of other genes involved in the lytic cycle. Satellite bacteriophage P4 deviates from this model in two respects. (i) Prophage immunity does not prevent transcription initiation of the operon encoding the replication functions (␣ operon); rather, it promotes premature termination of transcription that initiates at P LE , the constitutive promoter of the ␣ operon (9, 10, 12) . (ii) The immunity factor is not a protein but a small, 69-nucleotide (nt) RNA (CI RNA) exhibiting complementarity with the nontranslated leader region of the transcripts it regulates (10, 11a, 12) .
P4 depends on all the morphogenetic genes of a helper phage such as P2 to assemble the viral particle. Autonomous P4 replication requires the expression of a primase-helicase coded for by the P4 ␣ gene (14, 35) and leads either to the lytic cycle (when a helper phage genome is present in the host cell) or to a multicopy plasmid state (in the absence of the helper).
As an episome, P4 may also integrate in the host chromosome and establish the lysogenic condition (for a review, see reference 21).
Central to the choice and the maintenance of the lysogenic versus the lytic or plasmid condition is the regulation of P4 replication genes (Fig. 1) . Soon after infection of a sensitive host, transcription of the ␣ operon starts at the constitutive promoter P LE . Transcription from P LE seems to be intrinsically termination prone, and transcripts of different lengths (0.3 to 0.5, 1.3, and 4.1 kb) are produced. At a later time as well as in the lysogenic state, production of transcripts longer than 0.3 to 0.4 kb initiating at P LE is prevented by premature transcription termination (9, 10) . This is dependent on a functional immunity RNA factor (CI RNA) which is coded for by the untranslated leader region of the ␣ operon itself (cI gene) and is generated by the processing of the primary transcript (10, 11a, 12) (Fig. 1B) . A region in the CI RNA (seqB) exhibits high complementarity with seqA, a sequence immediately downstream of P LE . All P4 immunity-defective recessive mutants isolated so far carry a mutation in cI, and most of the mutations fall in seqB. This suggested that the P4 immunity factor controls termination of transcription that starts at P LE by specific RNA-RNA interactions between CI and the nascent transcript (10, 12) .
Thus, in P4, both immunity and replication functions are coded for by the same operon. Transcription from P LE of the operon distal portion, which encodes the replication functions, occurs only soon after infection, before the CI RNA immunity factor is produced by the processing of the primary transcript. Later on, transcription from P LE is restricted by enhancement of premature transcription termination efficiency to the proximal part of the operon which encodes the immunity factor itself.
Expression of the ␣ operon late in the lytic cycle and in the plasmid condition is made possible by activation of P LL , a positively regulated promoter located 400 nt upstream of P LE (9) . Transcription from P LL is insensitive to transcription termination controlled by P4 immunity, probably because translation of two open reading frames (orf88 and orf199) at the 5Ј end of the P LL mRNA protects the nascent transcript from the action of the immunity factor ( Fig. 1) (23a) .
To elucidate the peculiar immunity mechanism of P4 and understand how a small RNA may control transcription termination, it is fundamental to identify the target(s) of the RNA immunity factor. In this work, we show that the previously identified element seqA is indeed involved in the control of P4 immunity; moreover, we identify an additional site (seqC) in the untranslated leader region of the ␣ operon which is also complementary to seqB and is involved in P4 lysogenization. Evidence that seqA and seqC represent the target sites for the CI RNA immunity factor is presented.
MATERIALS AND METHODS
Bacteria, phages, and plasmids. The bacterial strains used were derivatives of Escherichia coli C-1a (prototrophic) (26) , C-2404 [galK(Am) recA] (12), C-5201 (polyauxotrophic str-1) (7), C-5202 (polyauxotrophic str-1 supD) (7) , and C-5505 (polyauxotrophic str-1 pcnB::Tn10) (12) and their P2 (P2 lg, a large plaque former) (2) and P4 lysogenic derivatives; in the text, the prophage is indicated in parentheses following the name of the parental strain. P4 derivatives and plasmids carrying P4 genome fragments are listed in Table 1 . The plasmid vectors used were pKO1 (23), pTTQ18 and pTTQ19 (30) , and pUC8 (33) . The cloned P4 DNA fragments are diagrammed in Fig. 1 . The P4 genome coordinates are from the updated P4 DNA sequence (GenBank accession number X51522) (15, 36) .
pGM318 was constructed by cloning the P4 8496 to 8693 region in pTTQ18. The region was obtained by PCR of P4 DNA with the oligos A and B being used as primers (see below) and by digestion with AluI. The kpn1 mutation was created by overlap extension and PCR amplification (see below) of P4 ϩ 8594 to 9127 with the mutated primers kpn4 and npk5. The fragment, digested with MluI(8623) and XmnI(9103), was cloned in pGM236 digested with the same enzymes, giving pGM324. seqA405 and seqA8 were created by overlap extension and PCR amplification of P4 ϩ 8594 to 8785 with the mutated primers 6-7 and 8-9, respectively. The fragments, digested with MluI (Klenow filled) and KpnI, were cloned in pUC18 SalI (Klenow filled)-KpnI, giving pGM322 and pGM323, respectively. The seqC405 mutation was created by overlap extension and PCR amplification of either P4 ϩ (to give pGM327) or the P4 cI405 (pGM326) 8303 to 8645 fragment with the mutated primers 10 and 11, whereas to produce seqC8 (pGM329), the oligos 12 and 13 were used. The fragments, digested with BglI(8371)-MluI(8624), were cloned in pGM13 treated with the same enzymes. The sequence of the cloned regions obtained by PCR was confirmed by sequencing.
All the site-specific mutations obtained by PCR mutagenesis were transferred in the phage genome by in vitro recombination of suitable restriction fragments, and the mutant phage was recovered by transfection of C-5202(P2) as described (1) . The genotype of the recombinant phage was confirmed by sequencing the relevant region.
Oligonucleotides and RNA probes. The oligonucleotides used for PCR are the following (the coordinates are those of the P4 sequence in the oligo 5Ј to 3Ј direction, and the base changes from the P4 sequence [P4 base-position-base change] are reported): oligo 6, 8679 to 8645, G8663A; oligo 7, 8647 to 8680,  C8663T; oligo 8, 8679 to 8645, A8662G; oligo 9, 8647 to 8680, T8662C; oligo 10,  8393 to 8426, C8411T; oligo 11, 8426 to 8394, G8411A; oligo 12, 8393 to 8426,  T8410C; oligo 13, 8426 to 8394, A8410G; oligo A, 8361 to 8380; oligo B, 8693 to  8680; oligo kpn4, 8793 to 8759, G8772C; oligo npk5, 8749 to 8783, C8772G; oligo vir ϩ , 9088 to 9110; and oligo vir1, 9088 to 9110, G9099A. The ␥-32 P-labelled RNA probes P LE -t2 and SeqB were prepared as described (10) and cover P4 8418 to 8774 and 8418 to 8470, respectively.
P4 mutagenesis and screening of P4 virulent mutants by lysis spot hybridization. UV light mutagenesis of P4 was performed as described by Ghisotti et al. (12) . To identify virulent mutants, the P4 clear plaques obtained were purified and replica plated on C-5201(P2)(P4). Spontaneous virulent mutants were obtained by plating about 10 8 P4 PFUs on the P2-P4 double lysogen. To distinguish between vir1-like (promoter up mutations in P LL ) and virulent mutants of a different kind, spontaneous and UV-induced virulent phages were hybridized to 32 P-labelled vir1 or vir ϩ oligonucleotides corresponding to either the P4 vir1 or the P4 ϩ Ϫ10 region of the P LL promoter, respectively. P4 virulent plaques were resuspended in microtiter wells and replica plated on C-5201(P2 lg) indicator. The P4 DNA of the lysis spots was immobilized on two nitrocellulose filters as described previously for phage lambda plaques (25) , and the filters were hybridized to vir1 and vir ϩ oligonucleotides that were 5Ј end labelled with T4 polynucleotide kinase in the presence of [␥-
32 P]ATP, as described previously (25) . Hybridization was performed in 6ϫ SSC (1ϫ SSC is 0.15 M NaCl plus 0.015 M sodium citrate) (pH 7) containing 0.05% sodium pyrophosphate and 0.5% sodium dodecyl sulfate at 48ЊC for 18 h. The filters were washed three times at room temperature and once at 58ЊC with 6ϫ SSC-0.05% sodium pyrophosphate. These conditions allowed specific hybridization only to the fully complementary DNA, whereas a single mismatch was sufficient to prevent hybridization.
Base-directed mutagenesis by PCR overlap extension. Specific base substitution mutants were generated by the procedure described by Ho et al. (17) . In summary, two complementary synthetic oligonucleotides carrying the desired base substitution and two external primers were used in two independent PCRs to generate two DNA fragments having one overlapping end sequence. These two fragments were combined in a subsequent PCR in which the annealed overlapping ends of each strand served as primers for the 3Ј extension on the complementary strand, thus generating a fusion DNA molecule further amplified by the external primers. The fragment so obtained was cut by restriction enzymes and cloned in a suitable plasmid. Both strands of the region containing the mutation to be used for the construction of other recombinant plasmids and phage were fully sequenced. In order to limit the region to be sequenced and to facilitate the transfer of the desired mutation in P4, we created the kpn1 mutation in pGM324 by PCR mutagenesis and transferred it in P4. P4 kpn1, which carries a unique KpnI restriction site, was then used for all subsequent P4 mutant strain constructions.
Complementation test of P4 clear plaque mutants. Ten microliters (each) of two clear plaque mutant stocks of about 10 8 PFU ml Ϫ1 were cross streaked on C-5201(P2 lg) indicator. Turbid indicator outgrowth at the crossing of the two clear streaks indicated complementation for immunity.
P4 one-step growth and screening for P4 lysogens in a P2 lysogenic host. The bacterial strains were grown at 37ЊC in LD broth (1% tryptone, 0.5% yeast extract, 0.5% NaCl) supplemented with 5 mM CaCl 2 (to allow P4 adsorption) and 100 g of ampicillin ml Ϫ1 (if the strain carried an Amp r plasmid) to 40 Klett colorimeter units, equivalent to 10 8 cells ml
Ϫ1
. When induction of the P tac promoter of the resident plasmid was required, IPTG (isopropyl-␤-D-thiogalactopyranoside) was added to a final concentration of 40 g ml Ϫ1 and the cultures were further incubated for 1 h at 37ЊC and diluted to 40 Klett units before the infection. The cells were then infected with P4 with the intent of achieving a multiplicity of infection of 10 and incubated at 37ЊC. After 15 min, phage adsorption was measured and P4 antiserum (K value, 1) was added to inactivate the unadsorbed phage; after 20 min, the cells surviving the infection and the cells yielding phage progeny (yielders) were assayed. A culture sample was diluted 10 4 -fold in LD (with ampicillin if the strain carried an Amp r plasmid) and incubated for 40 min at 37ЊC with aeration, and the phage titer produced was assayed. The clones surviving the infection were analyzed for lysogeny by testing their ability to release the prophage and their sensitivity to P4 cI405 and P4 vir1.
Infection with P4 and screening for P4 lysogens and plasmid carriers in the absence of P2 (cox test). Cell growth, infection with P4, and measurement of the survivors were performed as in the one-step-growth experiment. The screening of the lysogens and P4 plasmid carriers among the survivors was performed as described previously (8) . The test is based on the fact that the helper P2 cox gene is necessary to induce the P2 lytic cycle upon P2 infection of a P4 lysogen but is not required when P4 is in the plasmid condition (8, 29) . Thus, the P4 lysogens were identified as the clones that released P4 following infection with P2 cox ϩ but not with P2 cox4, whereas P4 plasmid carriers among the survivors released P4 following infection with both P2 cox ϩ and P2 cox4. Northern (RNA) blot hybridization. RNA was extracted from E. coli and from P4-infected cells as described previously (9) formamide-formaldehyde agarose or 10% polyacrylamide-urea denaturing gel electrophoresis, following the procedure detailed by Sambrook et al. (25) . RNA was transferred from the agarose gels onto Hybond-N filter membranes (Amersham) by vacuum blotting and from the acrylamide gels onto the same type of membranes by electroblotting. Hybridization to the specific riboprobes was performed as described previously (10) .
RESULTS
Transcription of cloned seqA interferes with the establishment of P4 immunity. In a previous study, it was shown that a cloned 357-bp fragment of P4 DNA encompassing P LE , seqA, and cI (pGM152 on Fig. 1B ) conferred P4 immunity to the bacterial host, thus preventing P4 plaque formation, whereas shorter fragments (pGM230 and pGM306) containing P LE and seqA caused P4 to make clear plaques. An even shorter fragment (pGM156) missing the distal part of seqA did not affect the P4 turbid plaque morphology. This suggested that the presence of seqA without cI on the plasmid vector interfered with P4 lysogenization by titrating out the immunity factor produced by the superinfecting phage and that interactions between the complementary sequences seqA and seqB might be involved in P4 immunity control (10, 12) . To define whether the cloned fragments discussed above would actually interfere with P4 immunity establishment and/or maintenance, we tested their effect on the choice of the lysogenic versus the lytic or plasmid condition. Cells harboring the appropriate plasmid were infected with P4; 20 min later, we assayed the cells surviving the infection and, in the P2 lysogen, the cells producing P4 phage (yielders). The survivors were then tested for P4 lysogeny and, in the P2 nonlysogenic host, for the presence of P4 in the plasmid condition, as described in Materials and Methods. The lysogenization index was calculated as the ratio of the lysogenic cells to either the yielders or the P4 plasmid carriers. To avoid recombination between the infecting phage and the resident plasmid, the experiments were performed in recA hosts.
In the P2 lysogenic host (Table 2) , the cloned P4 fragments containing both P LE and seqA (pGM230 and pGM306) caused a reduction of the cell fraction surviving P4 infection and an increase in yielder frequency by comparison with the controls (the vector pKO1 and pGM156 that carries P LE and only the 5Ј half of seqA). In the absence of P2 (Table 2 ), pGM230 and pGM306 greatly increased the frequency of clones carrying P4 as a plasmid. Nevertheless, P4 lysogens could be recovered both in the presence and in the absence of P2. Thus, it appeared that the P4 cloned fragments would favor the lytic cycle and the establishment of the plasmid state and greatly reduce the lysogenization index. We shall call this effect anti-immunity.
To define more precisely the elements required for antiimmunity, we made deletions of either seqA (pGM307) or P LE (pGM304 and pGM305) (the former is missing the Ϫ35 region of P LE , whereas in the latter, the deletion completely removes the promoter and the first 4 nt of seqA [ Fig. 1]) . Deletion of either seqA or P LE was sufficient to abolish the anti-immunity effect (see data for pGM307, pGM304 and pGM305 [ Table 2] ). Moreover, a plasmid carrying the seqA region under the control of the inducible promoter P tac (pGM318) exhibited the anti-immunity effect only when transcription was induced by IPTG ( Table 2 ), suggesting that transcription of the seqA region was necessary for the anti-immunity effect to occur. IPTG did not affect the outcome of P4 infection in the control plasmid pGM317 in which seqA can be transcribed both from P tac and the constitutive promoter P LE .
The P4 lysogens of the strains carrying the anti-immunity plasmids could be stably maintained. In the presence of P2, the titer of P4 spontaneously released by the strains carrying the anti-immunity fragments was 10-to 100-fold higher than that of control strains; in the absence of P2, segregation of P4 plasmid carriers was detectable in the strain carrying pGM306 (up to 50% of P4 plasmid-carrying clones in overnight cultures) but was below the detection limit (Ͻ10 Ϫ3 ) with pGM230.
These data indicate that transcription of the P4 seqA region from a plasmid vector interferes with the establishment of P4 immunity but that it is compatible with the maintenance of the lysogenic state.
Transcription of the P4 ␣ operon from P LE in the presence of anti-immunity plasmids. We then tested whether the antiimmunity plasmids would interfere with the normal P4 transcription pattern from P LE . Cells carrying either the anti-immunity plasmid pGM230 or the control vector pKO1 were infected with P4; the RNA was extracted at different times after infection and analyzed by Northern blot hybridization with a P LE proximal probe. As can be seen from Fig. 2A , the early 4.1-kb mRNA, which covers the entire ␣ operon, was no longer detectable 20 min after infection of control cells, as previously observed (9, 10) . In contrast, in cells carrying the anti-immunity plasmid pGM230, the amount of the 4.1-kb mRNA greatly increased up to 20 min after P4 infection (expression of the 1.3-kb mRNA produced by P4 could not be analyzed in this experiment because of the presence of transcripts of a similar size produced by pGM230). This RNA species, however, almost disappeared 60 min after infection and could not be detected in the P4 lysogen. We also used Northern blot hybridization with a CI RNA specific probe to examine whether the anti-immunity plasmid would interfere with the production of the P4 immunity factor. As can be seen from Fig. 2B , no substantial difference between the anti-immune host and the control was apparent with respect to the time and the amount of CI RNA production. It thus appears that the presence of the anti-immunity plasmid greatly delays the shutoff of long mRNAs originating at P LE upon P4 infection. However, the anti-immunity plasmid did not interfere significantly either with the synthesis of the CI RNA or with the P4 transcription pattern of a lysogenic cell.
Effect of seqA mutations on anti-immunity. The simplest explanation for the anti-immune effect is that the RNA produced by the cloned fragment titrates out the CI RNA produced by the infecting phage; this would delay the turnoff of long-mRNA production, thus opposing the establishment of P4 immunity.
Titration of the P4 immunity factor could depend on RNA-RNA interactions between the complementary sequences seqA and seqB. To test this idea, we introduced two mutations in the anti-immunity fragment of pGM306 by in vitro site-specific mutagenesis (17) and tested their effect on anti-immunity. These mutations altered the complementarity of seqA with seqB (seqA8 [A8662G] and seqA405 [G8663A]) (Fig. 3) . For reasons that will become apparent, the base substitutions seqA8 and seqA405 were such as to restore complementarity with the mutated seqB of the known P4 immunity-defective mutants ash8 and cI405, respectively. The seqA405 mutation in pGM322 abolished anti-immunity, as evidenced by the turbid plaques made by P4 on a strain carrying this plasmid, thus supporting the idea of a seqA-seqB interaction via complementary base pairing. The seqA8 mutant plasmid (pGM323), however, still caused P4 to form clear plaques and thus exhibited the anti-immunity effect. This might be due to the fact that the A-to-G transition in seqA8 may still allow pairing with the corresponding U in seqB.
seqA is necessary for P4 immunity. The data given above support the hypothesis that seqA is an RNA target for the P4 CI immunity factor. However, they do not define the role that seqA may play in the bacteriophage immunity mechanism, in which seqA might function either as an anti-immunity determinant or as an element necessary for immunity. To investigate this further, we transferred the seqA mutations into P4 by in vitro recombination. Both P4 seqA8 and P4 seqA405 made clear plaques and were unable to lysogenize in both P2 lysogenic and nonlysogenic strains (Table 3) ; however, contrary to the expectation for mutants in the target of the immunity factor, they did not form plaques on P4 lysogenic hosts and were therefore sensitive to P4 immunity (Table 4 and data not shown). This suggests either that seqA is not a target for the immunity factor or that an additional target(s) is involved in the P4 immunity mechanism and that multiple mutations are required for virulence.
In a cross-streak complementation test with P4 clear plaque mutants (see Materials and Methods), P4 seqA8 and seqA405 mutants did not complement one another or cI mutants for immunity (the streaks remained clear at the crossing with P4 cI405, P4 ash3, and P4 ash29), whereas complementation was observed (turbid area at the crossing) with P4 cIIam3, a clear plaque mutant that belongs to the cII complementation group (4, 13). Thus, both P4 seqA8 and seqA405 appear to be recessive immunity-sensitive mutants.
Isolation of P4 mutants insensitive to immunity: identification of the seqC locus. In order to identify the target(s) for the P4 immunity factor, we sought mutants that were insensitive to immunity. The only virulent mutant characterized so far, P4 vir1, carries a promoter up mutation in the Ϫ10 region of P LL and activates transcription from this promoter, which is insensitive to transcription termination controlled by P4 immunity (9, 20, 22) .
To identify virulent mutants of a different kind, we screened P4 virulent mutants by plaque hybridization with 32 P-labelled oligonucleotides corresponding either to the wild type or to the vir1 Ϫ10 region of P LL (see Materials and Methods). In a first survey of spontaneous and UV-induced P4 virulent mutants derived either from a wild-type phage or from immunity-defective cI mutants (ash8, ash9, cI9, cI10, and cI405) (Table 1), 14 out of 14 independent mutants analyzed carried a mutation in P LL . It thus appears that when P4 virulent mutants are selected for, P LL promoter up mutations are most likely obtained.
To circumvent this problem, we selected for virulent derivatives of P4 ash29 and P4 seqA405 cI405 mutants. ash29 (G8433A) is a pleiotropic mutation that confers a weak immunity defect on P4 and suppresses the virulence of P4 vir1 (19, 27a) . This latter phenotype appears to be due to the polarity of the amber mutation created in orf199 that leads to the premature termination of transcription starting at P LL (23a). The suppression of virulence could therefore decrease the incidence of P LL promoter up mutations. On the other hand, if multiple mutations were required for virulence, the presence of seqA405 could increase the frequency of virulent mutants.
From P4 ash29, we obtained and analyzed two independent virulent derivatives that hybridized only to the oligo vir ϩ and carried an additional mutation (seqC30 and seqC31, respectively); both mutations turned out to be the same C8382A transversion. From P4 seqA405 cI405, we isolated the virulent derivatives seqC32 (G8419T) and seqC33 (T8407C). These 
VOL. 177, 1995
TARGET SITES OF PHAGE P4 IMMUNITY RNA FACTOR 1429 mutations drew our attention to a region we called seqC, which, like seqA, presents high complementarity with seqB. seqC is located downstream of cI and is split into two portions, seqCЈ (8402 to 8424) and seqCЉ (8362 to 8384), by a 17-nt sequence with hyphenated dyad symmetry; all of the spontaneous mutations in seqC listed above are changes in bases complementary to seqB ( Fig. 1 and 3 ).
The isolation of such mutants indicates that seqC is involved in the control of P4 immunity. To study its role, we constructed a P4 seqC30 single mutant by in vitro recombination; moreover, we created two additional mutations in seqC by basespecific mutagenesis. These mutations, seqC8 (A8410G) and seqC405 (G8411A) (see Materials and Methods) (Fig. 3) , altered the complementarity with seqB; such mutations would also restore the complementarity of seqC with seqB for ash8 and cI405 mutants, respectively. Then, by in vitro recombination, we constructed a number of P4 mutants carrying single or multiple mutations in seqA, seqB, and seqC (Table 1) and tested their effect on P4 lysogenization (Table 3) .
In a P2 lysogenic strain, both P4 seqC30 and P4 seqC405 single mutants gave clear plaques and were defective in lysogenization. In the absence of the helper, both P4 lysogens and plasmid-carrying clones could be obtained, although both types appeared to be unstable (Table 3) . However, like the seqA mutants, the seqC single mutants could not form plaques on a P2-P4 double lysogen (Table 4 and data not shown); thus, they were still sensitive to P4 prophage immunity. By a cross-streak complementation test, they appeared to belong to the cI complementation group. In contrast, P4 seqA405 seqC405 was able to grow on a P4 lysogen as well as on a strain expressing P4 immunity from a multicopy plasmid (pGM152); thus, the double mutant exhibited a virulent phenotype (Table 4) .
P4 seqC8 formed turbid plaques and did not seem to be affected in lysogenization (Table 3) ; the double mutant P4 seqA8 seqC8 gave clear plaques like those of the single seqA8 mutant and was still sensitive to wild-type P4 immunity (data not shown).
Effect of a compensatory mutation in seqB on P4 seqA405 seqC405 virulence. The data given above indicate that both seqA and seqC regions must be mutated in order to make a P4 phage insensitive to the prophage immunity. This suggests that both seqA and seqC represent functional targets for the P4 CI immunity factor. If CI RNA-target interactions depend on the complementarity of seqB with both seqA and seqC, a compensatory mutation in seqB that restored the complementarity between the CI RNA and the mutant target sites should also restore immunity. To test this prediction, we constructed the triple mutant P4 seqA405 cI405 seqC405 and assayed its ability to lysogenize a sensitive host. As can be seen from Table 3 and 4, the cI405 compensatory mutation in the phage was not sufficient to restore the ability to form turbid plaques and to lysogenize. However, neither this triple mutant nor the virulent P4 seqA405 seqC405 double mutant could grow lytically when a CI RNA carrying the cI405 mutation was expressed from a multicopy plasmid (pGM85), whereas they were insensitive to the wild-type immunity expressed by pGM152. Surprisingly, P4
ϩ could not grow with either pGM152 or with pGM85 (Table 4) (see Discussion).
Transcription pattern of P4 seqA and seqC mutants. The effect of the P4 mutations discussed above on transcription from P LE was then tested by Northern blot analysis. The results are shown in Fig. 4 . Unexpectedly, the kpn1 mutation, which was introduced into P4 in order to facilitate the in vitro construction of P4 mutant strains, altered the wild-type transcription pattern even though it was located upstream of P LE and did not affect P4 lysogenization efficiency. In P4 kpn1, the synthesis of the 4.1-and 1.3-kb transcripts was delayed and the peak of the production of these mRNAs occurred 20 min postinfection (in the P4 wild type, the peak is at 10 min) (9, 10) . Nevertheless, at 60 min postinfection, the 4.1-and 1.3- kb   FIG. 4 . Northern blot analysis of ␣ operon transcription in P4 seqA, seqB, and seqC mutants. RNA extracted from strain C-1a infected with P4 was fractionated by 1.5% agarose gel electrophoresis and analyzed by Northern blot hybridization with the riboprobe P LE -t2. The infecting phage mutants and the times after P4 infection of the RNA extractions (in minutes) are indicated at the top of the figure (Ϫ, noninfected cells) . The sizes of the P4 ϩ transcripts (10) are indicated in kilobases at the left. All the phages used carried the additional kpn1 mutation. C-1a) or yielders (in the P2 lysogen) among infected cells. e These plasmid carriers were unstable and gave cured clones upon streaking. f P4 induction by P2 was cox independent; however, these clones were rather unstable and segregated cox-dependent clones upon streaking (see Materials and Methods).
g P4 induction by P2 was cox dependent; however, these clones were rather unstable and segregated cox-independent clones upon streaking. For all the seqA and seqC single mutants that were affected in lysogenization (thus excepting seqC8), the turnoff of the 4.1-and 1.3-kb RNAs was further delayed relative to that for the P4 kpn1 control. In such mutants, a substantial amount of the 4.1-and 1.3-kb transcripts was still present 60 min after infection, and this was larger in seqA than in seqC mutants (Fig. 4) . None of the tested seqA or seqC single mutants produced detectable amounts of RNA longer than 300 to 400 nt upon infection of a P4 lysogen (data not shown).
The virulent mutants P4 ash29 seqC30 and P4 seqA405 seqC405 did not turn off expression of the 4.1-and 1.3-kb transcripts even 60 min postinfection and produced this mRNA species even in the presence of P4 immunity (Fig. 4 and  data not shown) . Interestingly, the triple mutant P4 seqA405 cI405 seqC405, although unable to establish immunity, turned off the late expression of the 4.1-and 1.3-kb mRNAs. Thus, restoration of complementarity between seqB and seqA or seqC suppressed the transcription termination defect observed in the single and double mutants.
The short transcripts from the immunity region were analyzed by acrylamide gel electrophoresis, Northern blotting, and hybridization to riboprobes specific for either the whole immunity region (Fig. 5) or the CI RNA (data not shown). P4 seqA mutants produced a higher amount of the 300-to 400-nt RNAs than did P4 seqC, both in the absence and in the presence (data not shown) of P4 immunity; however, none of these mutants was affected in the ability to produce the CI RNA.
DISCUSSION
Identification of seqA and seqC as targets for the P4 CI RNA immunity factor. Expression of several operons is known to be controlled by an RNA molecule rather than by a protein. In most cases analyzed so far, the RNA effector pairs to a complementary region on the transcript to be regulated (cis-acting element), and this interaction may be directly involved in the control of transcription elongation, RNA stability or processing, or translation efficiency (for reviews, see references 11, 27, and 34). Expression of the P4 ␣ operon is controlled by the CI RNA coded for within the untranslated leader region of the ␣ operon itself. The CI RNA is the trans-acting factor that prevents transcription of the P LE distal part of the operon, thus conferring superinfection immunity (10, 11a, 12) . In this work, we have presented evidence that two regions highly complementary to seqB within the CI RNA, seqA and seqC, are the targets of the P4 RNA immunity factor and are required in cis for the negative control of P4 ␣ operon expression.
seqA was identified in a previous work (12) as a region immediately downstream of P LE that exhibits complementarity to seqB. Since most recessive immunity-deficient mutations occurred in seqB and altered the complementarity to seqA, it was suggested that interactions between CI RNA and the nascent transcript would promote premature transcription termination of the operon (10, 12) . In this work, we show that seqA is a key element in the P4 lysogenization mechanism since mutations in seqA (seqA8 and seqA405) that decrease complementarity with seqB make P4 unable to lysogenize and efficiently shut off transcription of the ␣ operon. However, these mutations do not allow the mutant phage to escape P4 immunity, thus suggesting that seqA cannot be the only cis-acting site interacting with the CI RNA.
The presence of a second cis-acting site (seqC) involved in the immunity control was revealed by the isolation of P4 virulent mutants that carried either double or triple mutations in the immunity region. Single mutations in seqC (seqC30 and seqC405) reduce P4 lysogenization proficiency, whereas mutations in both seqA and seqC (P4 seqA405 seqC405, P4 seqA405 cI405 seqC32, and P4 seqA405 cI405 seqC33) are required for virulence. The dominant phenotype of the double mutants suggests that seqA and seqC represent the target sites for the CI RNA immunity factor. Both functional sites are necessary to efficiently establish and/or maintain immunity upon infection, whereas a single site appears to be sufficient to make a superinfecting phage susceptible to immunity already established in the host. The immunity-defective phenotype exhibited by the seqA and seqC single mutants could be accounted for by the increased persistence of the 4.1-and 1.3-kb transcripts from P LE produced upon infection. These transcripts encode ␣ and other genes necessary for P4 replication and the lytic or plasmid cycle, and a prolonged expression of such functions could prevent establishment of lysogeny and/or favor the establishment of the alternative developmental pathways.
P4 immunity requires interactions between seqB and seqA or seqC. Most P4 immunity-defective mutants in the cI gene carry a mutation in seqB that reduces the complementarity to both seqA and seqC (11a, 12) (Fig. 3) . All of the spontaneous mutants we obtained in seqC affect complementarity to seqB, and three out of four mutants obtained by base-specific substitution in seqA and/or seqC have altered immunity. These observations indicate that complementarity between seqB and seqA or seqC is relevant for P4 immunity.
The most obvious target for an RNA effector is a complementary RNA molecule. Evidence that CI RNA may interact with another RNA molecule by pairing to the complementary sequence seqA can be found in the analysis of the anti-immunity effect. Transcription of seqA is required for anti-immunity, and anti-immunity may be abolished by a mutation in seqA, decreasing complementarity with seqB.
On the basis of these data, we suggest a basic model for P4 immunity. (i) The CI RNA is the trans-acting immunity factor.
(ii) The CI RNA interacts with the RNA transcribed from P LE by base pairing of seqB with the complementary regions seqA and seqC (Fig. 3B) ; intramolecular pairing of seqB with either seqA or seqC might occur as well. (iii) As a consequence, transcription from P LE terminates prematurely and expression of P4 replication genes is prevented. FIG. 5 . Northern blot analysis of the transcripts from the immunity region of P4 seqA and seqC mutants. The RNA was fractionated by 10% acrylamide-7 M urea gel electrophoresis, electroblotted, and hybridized to probe P LE -t2. The sizes of the transcripts are indicated in kilobases at the left. The times after infection of the extractions (in minutes) are indicated at the top of the figure (Ϫ, noninfected cells). All the phage used carried the additional kpn1 mutation.
A role for seqC in the transcription termination mechanism is suggested by the observation that the distal part of seqC, seqCЉ, overlaps the ribosome-binding site and the start codon of kil, the first translated gene downstream of P LE (11a, 12) (Fig. 3) . The pairing of seqB with seqC might prevent translation of kil and cause premature transcription termination by a polar effect.
Mutations in seqA have a more drastic effect on P4 immunity and transcription termination of the ␣ operon than do mutations in seqC, since no P4 lysogens could be isolated and the long transcripts from P LE were abundantly expressed up to 1 h after P4 seqA infection. It might be suggested that seqA-seqB pairing may promote transcription termination, for example, by allowing the formation of alternative RNA secondary structures that favor RNA polymerase pausing and release and/or the recruitment of host transcription termination factors.
Virulent mutants of P4. Transcription from the late promoter P LL is insensitive to the termination mechanism controlled by P4 immunity (10) . Thus, vir1-like mutants, which carry mutations that make P LL independent of its positive regulator (9, 20, 23a) , do not provide information on the targets of the trans-acting immunity factor.
The second class of P4 virulent mutants we have isolated carry a mutation both in seqA and in seqC. This strongly suggests that seqA and seqC are the cis-acting elements required for P4 immunity sensitivity. The need for a double mutation to create this type of virulent mutant explains why the virulent mutants obtained in vivo most frequently carried a P LL promoter up mutation.
A third class of virulent mutants is represented by P4 ash29 seqC30. The single seqC30 mutation does not confer a virulent phenotype, so it appears that the peculiar combination of ash29 and seqC30 is required for P4 immunity insensitivity. An analysis of this virulent mutant might help an understanding of the molecular details of the P4 immunity process.
A compensatory mutation in seqB that restored complementarity with the mutant seqA and seqC (see the triple mutant P4 seqA405 cI405 seqC405) also restored premature transcription termination, therefore preventing late transcription of the whole ␣ operon from P LE . However, the compensatory mutation could not reestablish lysogenization proficiency. It may be suggested that small differences in the timing and/or efficiency of premature transcription termination may be relevant for the choice of the lysogenic condition. This could be influenced by the stringency of the seqB interaction with seqA or seqC. It should be noted that in these mutants, a UA pairing substitutes for the wild-type CG interaction (Fig. 3) . It is possible that this weaker interaction is sufficient to substantially terminate transcription upon infection when a large amount of CI RNA is produced but may be too leaky to fully prevent ␣ operon expression and maintain immunity. High levels of CI RNA may compensate for a weaker seqB interaction with seqA or seqC. In fact, P4 seqA405 seqC405 and P4 seqA405 cI405 seqC405 mutants do not grow in the presence of CI405 RNA (UA pairing) expressed by a multicopy plasmid but do form plaques with CI ϩ RNA (CA mismatch); on the other hand, a P4 wild type cannot grow with either a wild-type CI (CG pairing) or CI405 (UG pairing) RNA. However, when the plasmid expressing the CI405 RNA is carried in a low copy number, both P4 ϩ and the double and triple seq mutants can grow (data not shown).
P4 immunity establishment versus maintenance. Both seqA and seqC single mutants are sensitive to the P4 CI immunity factor since (i) they do not grow on a P4 lysogen (in such a host, transcription of these phage mutants from P LE is efficiently terminated) and (ii) in cross-streak complementation tests with either P4 ϩ or P4 cII, they form a turbid spot. On the other hand, both types of mutants produce a wild-type CI RNA. It is therefore somewhat paradoxical that these mutants form clear plaques, do not lysogenize (seqA mutants) or lysogenize at a reduced frequency (seqC mutants), and are unable to complement cI mutants. It should be considered, however, whether a delay of a reduced efficiency of the ␣ operon transcription termination upon infection might allow the irreversible onset of the alternative lytic or plasmid pathway. Furthermore, the establishment of lysogeny may demand different (or more stringent) requirements than its maintenance. This idea is supported by other situations that greatly reduce lysogenization frequency without being incompatible with immunity maintenance, such as the anti-immunity effect due to the expression of the cloned seqA region or mutations in the transcription termination factor Rho of the host (8a).
Relationship to other systems. The retronphage R73 is related to P4, and the two phages share a high degree of homology (18, 31) . The putative R73 cI gene sequence presents six base changes, all in seqB. It is noteworthy that for five of these changes, there is a complementary base substitution in both seqA and seqC, and the sixth is a C3U transition, still compatible for pairing with the G in the target sequences. R73 is heteroimmune to P4 (27a). This supports the idea that the pairing of seqB to seqA or seqC is important for immunity and that immunity specificity is provided by seqA, seqB, and seqC sequences.
The control of P4 ␣ operon expression exhibits striking similarities to the regulation of the phage P1 immI operon that codes for the P1 antirepressor (6, 24; for a review, see reference 16). The immI untranslated leader region is processed to produce a 77-nt RNA (C4 RNA), the trans-acting factor that negatively regulates the operon (5, 6). The C4 RNA bears extended complementarity with the translation initiation signals of icd, the first gene of the operon (5, 24) . RNA-RNA interactions between these complementary sequences prevent translation of icd, thus preventing expression of the downstream antirepressor gene by causing Rho-dependent transcription termination (3) .
The predicted secondary structures of P4 CI and P1 C4 RNAs and of the leader transcripts of the two operons are remarkably similar, and a limited sequence homology can also be detected (21) . Thus, the two regulatory systems appear to be evolutionarily related.
P1 C4 RNA exhibits complementarity to both the upstream and the downstream sequences in the leader transcript. It seems, however, that the upstream sequence plays a different role in the two phages. In fact, in P1, only the downstream sequence is involved in the negative regulation of the operon, whereas the upstream sequence appears to antagonize this regulatory mechanism (5). In P4, both the upstream and the downstream sequences promote transcription termination. In P1, c4 indirectly enables the establishment and maintenance of lysogeny by controlling the expression of an anti-immunity factor, whereas in P4, the cI gene encodes the immunity factor itself. It is conceivable that the different physiological roles of the two regulatory systems caused two homologous molecular structures to evolve different functions.
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